Evelo Biosciences
What if…
The small intestine functions as a control center for the entire immune system?
It turns out…
We can identify specific strains of
microbes that target and engage with immune cells in the small intestine to
direct systemic immune responses for the treatment of inflammatory diseases and
beyond.
We can identify specific strains of
microbes that target and engage with immune cells in the small intestine to
direct systemic immune responses for the treatment of inflammatory diseases and
beyond.
Founded by 51¶¯Âþ in 2015, Evelo Biosciences (NASDAQ: EVLO) is a clinical-stage biotechnology company developing a novel platform of orally delivered medicines harnessing the central biology of the small intestinal axis, SINTAX. Evelo’s product candidates are pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles (EVs) developed to engage cells in the small intestine with systemic therapeutic effects. Evelo’s therapies have the potential to be effective, safe, well-tolerated, convenient, and affordable medicines to improve the lives of hundreds of millions of people at all stages of inflammatory disease.
Latest 51¶¯Âþ from Evelo Biosciences
- Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock 05.25.2022
- Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights 05.12.2022
- Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors 04.21.2022
- Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors 04.06.2022
- Evelo Biosciences Appoints Juan Andres to Board of Directors 12.05.2019
- Evelo Biosciences Announces the Appointment of David Epstein as Chairman of its Board of Directors 09.17.2019